UroGen Pharma Ltd. (URGN) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Next earnings call: 2026-08-05
(Q2 2026)
— full calendar
Earnings Reports
-
Urogen Pharma (URGN) Q1 2026: Zesturi Prescriber Base Grows 151%, Validating Community Penetration Strategy
May 06, 2026
-
UroGen Pharma (URGN) Q4 2025: Zesturi Launch Drives 21% Revenue Growth, Community Uptake Accelerates
March 02, 2026
-
UroGen Pharma (URGN) Q3 2025: Zesturi Prescriber Base Hits 54 as J-Code Bottleneck Delays Full Uptake
November 06, 2025
-
UroGen Pharma (URGN) Q2 2025: Zysturi Launch Expands Addressable Market to $5B Opportunity
August 07, 2025
-
UroGen Pharma (URGN) Q1 2025: UGN-102 Eyes $5B Market as ODAC Review Nears
July 07, 2025